RT Journal Article
T1 SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
A1 Robles-Zurita, José Antonio
A1 Boyd, Kathleen A.
A1 Briggs, Andrew H.
A1 Iveson, Timothy
A1 Kerr, Rachel
A1 Saunders, Mark P.
A1 Cassidy, Jim
A1 Hollander, Niels Henrik
A1 Tabernero, Josep
A1 Segelov, Eva
A1 Glimelius, Bengt
A1 Harkin, Andrea
A1 Allan, Karen
A1 McQueen, John
A1 Pearson, Sarah
A1 Waterston, Ashita
A1 Medley, Louise
A1 Wilson, Charles
A1 Ellis, Richard
A1 Essapen, Sharadah
A1 Dhadda, Amandeep S.
A1 Hughes, Rob
A1 Falk, Stephen
A1 Raouf, Sherif
A1 Rees, Charlotte
A1 Olesen, Rene K
A1 Propper, David
A1 Bridgewater, John
A1 Azzabi, Ashraf
A1 Farrugia, David
A1 Webb, Andrew
A1 Cunningham, David
A1 Hickish, Tamas
A1 Weaver, Andrew
A1 Gollins, Simon
A1 Wasan, Harpreet S
A1 Paul, James
K1 Cancer - Tratamiento
AB BACKGROUND: The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomisedcontrolled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) ofadjuvant chemotherapy in colorectal cancer.METHODS: In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followedup for 3–8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource usedata, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data.Quality-adjusted partitioned survival analysis and Kaplan–Meier Sample Average Estimator estimated QALYs and costs. Probabilisticsensitivity and subgroup analysis was undertaken.RESULTS: The 3M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: −0.086;0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3M under a wide range ofmonetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for theFOLFOX regimen, 3M had lower QALYs than 6M (not statistically significant).CONCLUSIONS: Overall, 3M dominates 6M with no significant detrimental impact on QALYs. The results provide the economiccase that a 3M treatment strategy should be considered a new standard of care.
PB Springer Nature
YR 2018
FD 2018-11-13
LK https://hdl.handle.net/10630/37211
UL https://hdl.handle.net/10630/37211
LA eng
NO Robles-Zurita, J., Boyd, K.A., Briggs, A.H. et al. SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. Br J Cancer 119, 1332–1338 (2018). https://doi.org/10.1038/s41416-018-0319-z
NO This work was supported by Medical Research Council (transferred to NETSCC—Efficacy and Mechanism Evaluation) (Grant Ref: G0601705) and Cancer Research UK Core CTU Funding (Funding Ref: C6716/A9894). The Study Sponsor was NHS Greater Glasgow & Clyde and University of Glasgow. Eudract Ref: 2007–003957-10; ISRCTN No.: 23516549.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026